Close Menu

NEW YORK – Sunesis Pharmaceuticals and Viracta Therapeutics announced on Monday that the two drugmakers will merge in an all-stock transaction and form a precision oncology-focused company publicly listed under Viracta's name.

The combined company, which will be headquartered in Cardiff, California, will advance Viracta's precision oncology pipeline of products against virus-associated cancers, including nanatinostat for the treatment of Epstein-Barr virus (EBV)-positive relapsed and refractory lymphomas.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.